CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
出版年份 2020 全文链接
标题
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
作者
关键词
-
出版物
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 24, Issue 9, Pages 5135-5145
出版商
Wiley
发表日期
2020-04-11
DOI
10.1111/jcmm.15156
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
- (2019) Paul Daniel et al. Frontiers in Oncology
- CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?
- (2019) Oren J. Becher EBioMedicine
- Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
- (2019) Jiayi Yu et al. CLINICAL CANCER RESEARCH
- A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
- (2019) Rui-Chao Chai et al. Frontiers in Genetics
- Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
- (2019) Jia Wang et al. CNS Neuroscience & Therapeutics
- DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide
- (2019) Mengting Zhao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway
- (2019) Xiao Yu et al. LIFE SCIENCES
- P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
- (2019) Paiyun Li et al. PLoS One
- Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
- (2018) M Arnedos et al. ANNALS OF ONCOLOGY
- Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins
- (2018) Jingshan Tong et al. CANCER RESEARCH
- Temozolomide-associated hypermutation in gliomas
- (2018) Serah Choi et al. NEURO-ONCOLOGY
- Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
- (2018) Kyle Knickelbein et al. ONCOGENE
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors
- (2018) Dongshi Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
- (2018) Jennie W. Taylor et al. JOURNAL OF NEURO-ONCOLOGY
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
- (2018) Shabierjiang JIAPAER et al. NEUROLOGIA MEDICO-CHIRURGICA
- CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
- (2018) Shom Goel et al. TRENDS IN CELL BIOLOGY
- A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
- (2018) Xiaoyue Chen et al. Nature Communications
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
- (2018) Priya K. Gopalan et al. Oncotarget
- FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors
- (2017) Jingshan Tong et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
- (2017) Smruthi Vijayaraghavan et al. Targeted Oncology
- Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
- (2017) Esther S. Kim et al. Targeted Oncology
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
- (2017) Fengquan Chen et al. Anti-Cancer Agents in Medicinal Chemistry
- GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
- (2016) Jianlong Li et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
- (2016) J Tong et al. ONCOGENE
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
- (2016) Minghui Liu et al. Oncotarget
- Targeting Breast Cancer with CDK Inhibitors
- (2015) Erica L. Mayer Current Oncology Reports
- PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
- (2013) Kelly L. Barton et al. PLoS One
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues
- (2010) Dante Amelio et al. RADIOTHERAPY AND ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started